Literature DB >> 25733579

β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.

Kenji Tanimura1, Hui Jin2, Tadahiro Suenaga2, Satoko Morikami3, Noriko Arase4, Kazuki Kishida2, Kouyuki Hirayasu5, Masako Kohyama2, Yasuhiko Ebina6, Shinsuke Yasuda7, Tetsuya Horita7, Kiyoshi Takasugi8, Koichiro Ohmura9, Ken Yamamoto10, Ichiro Katayama11, Takehiko Sasazuki12, Lewis L Lanier13, Tatsuya Atsumi7, Hideto Yamada6, Hisashi Arase14.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy complications. β2-glycoprotein I (β2GPI) complexed with phospholipid is recognized as a major target for autoantibodies in APS; however, less than half the patients with clinical manifestations of APS possess autoantibodies against the complexes. Therefore, the range of autoantigens involved in APS remains unclear. Recently, we found that human leukocyte antigen (HLA) class II molecules transport misfolded cellular proteins to the cell surface via association with their peptide-binding grooves. Furthermore, immunoglobulin G heavy chain/HLA class II complexes were specific targets for autoantibodies in rheumatoid arthritis. Here, we demonstrate that intact β2GPI, not peptide, forms a complex with HLA class II molecules. Strikingly, 100 (83.3%) of the 120 APS patients analyzed, including those whose antiphospholipid antibody titers were within normal range, possessed autoantibodies that recognize β2GPI/HLA class II complexes in the absence of phospholipids. In situ association between β2GPI and HLA class II was observed in placental tissues of APS patients but not in healthy controls. Furthermore, autoantibodies against β2GPI/HLA class II complexes mediated complement-dependent cytotoxicity against cells expressing the complexes. These data suggest that β2GPI/HLA class II complexes are a target in APS that might be involved in the pathogenesis.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25733579      PMCID: PMC4424631          DOI: 10.1182/blood-2014-08-593624

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

2.  Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.

Authors:  Kotaro Otomo; Tatsuya Atsumi; Olga Amengual; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Tetsuya Horita; Shinsuke Yasuda; Takao Koike
Journal:  Arthritis Rheum       Date:  2012-02

3.  Capacity of intact proteins to bind to MHC class II molecules.

Authors:  A Sette; L Adorini; S M Colon; S Buus; H M Grey
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

4.  HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients.

Authors:  M Savi; G F Ferraccioli; T M Neri; P Zanelli; P P Dall'Aglio; A Tincani; G Balestrieri; G Carella; R Cattaneo
Journal:  Arthritis Rheum       Date:  1988-12

5.  A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.

Authors:  Kristi L Allen; Fabio V Fonseca; Venkaiah Betapudi; Belinda Willard; Jainwei Zhang; Keith R McCrae
Journal:  Blood       Date:  2011-11-21       Impact factor: 22.113

6.  Neutrophil infiltration during inflammation is regulated by PILRα via modulation of integrin activation.

Authors:  Jing Wang; Ikuo Shiratori; Junji Uehori; Masahito Ikawa; Hisashi Arase
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

7.  Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome.

Authors:  R Schwarzenbacher; K Zeth; K Diederichs; A Gries; G M Kostner; P Laggner; R Prassl
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

8.  Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome.

Authors:  Cetin Agar; Gwendolyn M A van Os; Matthias Mörgelin; Richard R Sprenger; J Arnoud Marquart; Rolf T Urbanus; Ronald H W M Derksen; Joost C M Meijers; Philip G de Groot
Journal:  Blood       Date:  2010-05-12       Impact factor: 22.113

9.  Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant.

Authors:  T Atsumi; M Ieko; M L Bertolaccini; K Ichikawa; A Tsutsumi; E Matsuura; T Koike
Journal:  Arthritis Rheum       Date:  2000-09

10.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

View more
  10 in total

Review 1.  New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.

Authors:  Yuichiro Fujieda; Olga Amengual
Journal:  Eur J Rheumatol       Date:  2020-11-19

Review 2.  The Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid Syndrome.

Authors:  Si Cheng; Haibo Wang; Hong Zhou
Journal:  J Immunol Res       Date:  2016-10-27       Impact factor: 4.818

3.  Patient-derived anti-β2GP1 antibodies recognize a peptide motif pattern and not a specific sequence of residues.

Authors:  Philippe de Moerloose; Céline Fickentscher; Françoise Boehlen; Jean-Marie Tiercy; Egbert K O Kruithof; Karim J Brandt
Journal:  Haematologica       Date:  2017-05-26       Impact factor: 9.941

4.  Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism.

Authors:  Aneta Stachowicz; Michal Zabczyk; Joanna Natorska; Maciej Suski; Rafał Olszanecki; Ryszard Korbut; Jacek R Wiśniewski; Anetta Undas
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

5.  Kasabach-Merritt phenomenon with concurrent appearance of antiphospholipid antibodies in a patient with giant liver haemangioma.

Authors:  Hiroyuki Nakamura; Yuichiro Fujieda; Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Adv Pract       Date:  2018-10-24

6.  Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation.

Authors:  Manuel Serrano; Laura Morán; Jose Angel Martinez-Flores; Esther Mancebo; Daniel Pleguezuelo; Oscar Cabrera-Marante; Juan Delgado; Antonio Serrano
Journal:  Front Immunol       Date:  2019-12-23       Impact factor: 7.561

Review 7.  The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.

Authors:  Thomas McDonnell; Chris Wincup; Ina Buchholz; Charis Pericleous; Ian Giles; Vera Ripoll; Hannah Cohen; Mihaela Delcea; Anisur Rahman
Journal:  Blood Rev       Date:  2019-08-16       Impact factor: 10.626

Review 8.  Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody(ANCA)-associated vasculitis.

Authors:  Daisuke Tsukui; Yoshitaka Kimura; Hajime Kono
Journal:  J Transl Autoimmun       Date:  2021-03-03

9.  Abrogation of self-tolerance by misfolded self-antigens complexed with MHC class II molecules.

Authors:  Hui Jin; Kazuki Kishida; Noriko Arase; Sumiko Matsuoka; Wataru Nakai; Masako Kohyama; Tadahiro Suenaga; Ken Yamamoto; Takehiko Sasazuki; Hisashi Arase
Journal:  Sci Adv       Date:  2022-03-04       Impact factor: 14.136

Review 10.  Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.

Authors:  Martin Killian; Thijs E van Mens
Journal:  Front Cardiovasc Med       Date:  2022-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.